Earlier studies have shown that when people lose weight, it can help improve their sleep apnea. The US Food and Drug Administration approved Zepbound to treat obesity in November.

You could say that it’s difficult to mask the challenges that people with obstructive sleep apnea face every day. But if this pill from Apnimed, Inc. eventually gets approved by the U.S. Food ...

Recently, the U.S. Food and Drug Administration (FDA) expanded approval of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with ...

The first oral pill for obstructive sleep apnea (OSA) could be around the corner after pharmaceutical company Apnimed Inc. reported positive results from its stage III clinical trial. Currently ...

The two drugs have a different set of broader indications, with Zepbound also approved to treat sleep apnea in people with obesity, for example. Side effects can vary, too, sometimes making one ...

Zepbound's main ingredient is tirzepatide and is approved for weight loss and obstructive sleep apnea. Wegovy is a semaglutide medication and helps manage weight loss and cardiovascular health.

GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (NYSE: LLY) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help.